

1 **Clinical and Epidemiological Characteristics of the First Month of the Covid-19 Pandemic in Chile.**

2

3 Macarena R. Vial¹, Anne Peters², Inia Pérez¹, María Spencer², Mario Barbé¹, Lorena Porte¹, Thomas
4 Weitzel^{1,2}, Mabel Aylwin¹, Pablo Vial^{1,2}, Rafael Araos^{1,2,3*}, and Jose M. Munita^{1,2,3*}, for the CAS-
5 UDD Covid-19 Working Group[†]

6

7 ¹Facultad de Medicina Clínica Alemana, Universidad del Desarrollo (CAS-UDD).

8 ²Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina CAS-UDD.

9 ³Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R).

10

11 *Corresponding author:

12 Jose M. Munita

13 jmunita@alemana.cl

14 *Alternate corresponding author:

15 Rafael Araos

16 raraosb@alemana.cl

17 **Key words:** COVID -19, coronavirus, SARS-CoV-2, pneumonia

18 Word count abstract 249

19 Total word count 2569

20

21

22

23

24

25

26 **Abstract**

27 Introduction: Understanding the clinical course and outcomes of patients with Covid-19 in
28 underrepresented populations like Latin America is paramount. In this study, we report the
29 clinical characteristics of Covid-19 in Chile, with a focus on subjects requiring hospitalization
30 during the initial phases of the SARS-CoV-2 pandemic.

31 Methods: This is a single center study including all consecutive patients diagnosed with
32 Covid-19 during the first month of the pandemic. Demographics, clinical characteristics and
33 laboratory data were collected within 24 hours of admission. The primary outcome was a
34 composite of ICU admission or all-cause, in-hospital mortality.

35 Results: During the first month of the pandemic, 381 patients were confirmed as positive
36 for SARS- CoV-2 by molecular testing; 88 (23.1%) of them eventually required
37 hospitalization. Median age of the cohort was 39 years (IQR 31-49). Overall mortality was
38 0.7% and 18 (3.7%) out of the 88 subjects who required hospitalization either died and/or
39 required ICU. Increased body mass index (BMI), C-reactive protein levels (CRP) and the
40 SaTO2/FiO2 index on admission were independently associated with a higher risk of ICU
41 care or death.

42 Discussion: The lower mortality observed in our prospective cohort during the first month
43 of SARS-Cov-2 pandemic was lower than previously reported. This finding could be due to a
44 lower threshold for admission, a healthcare system not yet overburdened and a younger
45 population, among other factors. BMI, CRP on admission were strong predictors for ICU
46 care or all-cause, in- hospital mortality. Our data provide important information regarding
47 the clinical course of Covid- 19 in Latin America.

48 **Introduction**

49 In December 2019, a cluster of severe pneumonia of unknown etiology was reported in
50 Wuhan, Province of Hubei, China.¹ A rapid investigation determined that the agent involved
51 was a novel Coronavirus sharing significant sequence identity with bats and human-related
52 coronaviruses.^{2,3} The virus and its associated disease were named Severe Acute Respiratory
53 Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus disease 19 (Covid-19), respectively.
54 ⁴ Soon after its identification, SARS-CoV-2 spread globally causing tremendous burden to
55 health care systems and society as a whole. According to publicly available information, the
56 first case of Covid-19 in Chile was diagnosed on March 3, 2020. Initial cases were imported
57 from Europe, but family clusters and evidence of secondary transmission were rapidly
58 observed. Therefore, the Chilean government declared phase 4 (widespread, ongoing local
59 transmission) on March 16, 2020. Data from early clinical series have shed light on the
60 clinical presentation of Covid-19. After a median incubation time of 5 days,^{5,6} patients
61 developing symptoms usually present with an influenza-like illness, with fever, dry cough,
62 headache, odynophagia, and dyspnea as the most common symptoms¹. Interestingly, a
63 large proportion of subjects also report the development of anosmia and/or ageusia as one
64 of the cardinal symptoms of the infection. Early work from China showed that 80% of the
65 subjects with Covid-19 followed an uncomplicated course, 15% required hospital admission
66 and 5% developed a severe infection with a catastrophic respiratory failure needing critical
67 care support.⁵ The case-fatality rate is variable, ranging from 2.25% in the Republic of Korea
68 to 14.5 % in countries like Italy, with increasing age, and comorbidities being the most
69 important predictors of mortality.^{7,8} As Covid-19 spreads, and the number of cases

70 dramatically increases, a detailed description of Covid-19 in new geographical areas is
71 critical. Moreover, understanding the clinical course and outcomes of patients with Covid-
72 19 in underrepresented populations like Latin America is paramount. In this study, we
73 report the clinical characteristics of Covid-19 in Chile with a focus on subjects hospitalized
74 during the first month of the epidemic.

75

76 **Methods**

77

78 The study was conducted in Clínica Alemana de Santiago (CAS), a tertiary care not-for-profit
79 hospital in Santiago, Chile. CAS is a 442-beds healthcare facility that before the Covid-19
80 pandemic included 12 general and 10 cardiac intensive care unit (ICU) beds. The study was
81 approved by the Institutional Review Board, with a waiver of informed consent given that
82 data was collected as part of routine clinical practice and used in a de-identified manner.

83 All consecutive patients attending the Emergency Room and diagnosed with Covid-19
84 between March 3, 2020, and April 4, 2020, were included in this cohort. Laboratory testing
85 for SARS-CoV-2 infection was performed using a commercial reverse-transcriptase (RT)
86 polymerase chain reaction (PCR) of nasopharyngeal and oropharyngeal swab samples.⁹

87 Cases were identified using the central laboratory database and electronic medical records.

88 Only patients with a positive SARS-CoV-2 RT-PCR were included. Data was extracted from
89 the electronic medical records and entered into a REDCap database by a team of
90 researchers, after a training session led by the senior data manager investigator (AP). Two
91 study investigators (MS and AP) conducted weekly data audits to ensure the quality of the

92 collected data. Data collected included demographic information, comorbidities, clinical
93 presentation, as well as duration of symptoms, treatment, and outcomes. Laboratory values
94 were automatically extracted from the electronic medical records. The Charlson
95 Comorbidity Index (CCI) was used to summarize comorbidities. The score goes from 0 to 24,
96 with zero representing no comorbidities.¹⁰ Body Mass Index (BMI) was used to assess excess
97 body weight. Pulse oximetry saturation (SpO₂)/ Fraction of inspired oxygen (FiO₂) ratio was
98 used to assess respiratory exchange.

99 The primary outcome was a composite of ICU admission or all-cause, in-hospital mortality.
100 Variables used to assess risk factors for the main outcome were obtained within 24 hours
101 of admission.

102

103 Statistical analysis

104 Continuous and categorical variables were presented as median (IQR) and n (%),
105 respectively. Patient characteristics were compared by subgroups of interest using a chi-
106 square test, Fisher's exact test or the Mann-Whitney U test as appropriate. A two-tailed p-
107 value <0.05 was considered statistically significant for all analyses.

108 To explore risk factors associated with disease severity, univariable and multivariable
109 logistic regression models were used. We selected variables for the logistic regression
110 model based on previous findings and plausibility. A maximum of 8 variables were included
111 in the logistic regression model to avoid overfitting. All analyses were conducted using Stata
112 (Version 16.0. College Station, TX: StataCorp LLC).

113

114 **Results**

115 During the first month of the Covid-19 pandemic, 3679 subjects presented with possible
116 SARS-CoV-2 infection and tested by RT-PCR in our institution; 381 (10.4%) were confirmed
117 as positive and included for this study. The average time of symptoms at the time of initial
118 testing was 3.7 days (SD 3.8).

119 The median age of the cohort was 39 years (IQR 31-49) and 153 (52%) were female (Table
120 1). A total of 253 (66.4%) patients reported an epidemiological risk factor for acquiring
121 SARS-CoV-2, i.e. 206 had exposure to a confirmed case, and 47 had recently visited a high-
122 risk country, (16 reported both risk factors). Cough and fatigue were the most common
123 symptoms at presentation. A summary of the main demographic and clinical features of the
124 cohort is shown in Table 1.

125 *Subgroup of patients requiring hospitalization*

126 Among the 381 patients, 88 (23.1%) eventually required hospital admission, 51 of them were
127 hospitalized after an initial management as outpatients. The median time of symptoms at
128 the time of admission was 8 days (IQR 5-10). Hospitalized patients were generally older than
129 those managed as outpatients (median 49 vs. 37, $p < 0.001$) and had a higher CCS with 0.28
130 for outpatients and 1.38 for inpatients ($p < 0.001$). On the first day of hospitalization, 40
131 (45%) subjects were admitted to general wards, 41 (47%) to a step-down unit, and 7 (8%)
132 to ICU. Among subjects hospitalized in general wards and stepdown units, 10 (12%) patients
133 were subsequently transferred to the ICU. The median duration of hospitalization was 8 (4-
134 14.5) days and the median length of stay (LoS) in the ICU was 13 (5.3-17.8) days. A total of

135 82 (93%) patients had an imaging compatible with pneumonia; 39 (44%) required
136 supplementary O₂ only, 20 (23%) non-invasive ventilation and 10 (11%) invasive ventilation.
137 Median days of invasive ventilation were 7.5 (6.3-15.3). Among those hospitalized, excess
138 body weight (62.5%) and hypertension (28%) were the most common coexisting conditions
139 A summary of the laboratory abnormalities on admission is presented in Table 3 and Figure
140 1. The most common laboratory abnormalities were: lymphopenia, increased levels of C-
141 reactive protein (CRP) and D-dimer. Ferritin values were available for 25 patients at
142 admission, with 20 (80%) presenting an increased level. A comparison of patients who
143 presented severe disease, defined as need for ICU care at any time during admission or in-
144 hospital death, with non-severe disease is provided in Table 3. In univariate analysis, odds
145 of ICU care/death were higher in males, and those with higher BMI, older age, a history of
146 diabetes or hypertension, and chronic medication such as steroids, angiotensin-converting
147 enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). Increased white blood
148 cells, neutrophils, CRP, procalcitonin, ferritin, D-dimer, bilirubin, troponin T, LDH and lower
149 SaTO₂/FiO₂, prothrombin time, sodium, albumin and lymphocytes were all associated with
150 the need for ICU care or death. Based on clinical plausibility and significance level on the
151 univariate analysis, the following variables were included in the multivariate logistic
152 regression model: age, gender, CRP, BMI, neutrophil lymphocyte ratio, SaTO₂/FiO₂, D-dimer
153 and sodium. Increased BMI and CRP levels were independently associated with increased
154 odds of ICU care/death. SaTO₂/FiO₂ had a p-value of 0.051, not significant according to our
155 predetermined level of 0.05. See Table 3. As of July 31, out of the 88 patients who required

156 hospitalization, a total of 3 patients had died and 85 had been discharged and remained
157 alive.

158 **Discussion**

159 Chile has been one of the most affected countries by the spread of SARS-Cov-2 worldwide,
160 and still struggling to contain the first wave of the Covid-19 pandemic. We report the first
161 prospective cohort of patients with Covid-19 in Chile and one of the few available for Latin
162 America and other developing regions. The 381 patients of our cohort encompass all
163 patients diagnosed at our institution during the first month of the pandemic and represent
164 a significant proportion of all notified cases in Chile during the study period (n = 4,161). The
165 cohort mirrored the beginning of the epidemic curve (first four weeks), when a large
166 proportion (~65%) of patients remained able to identify a risk of exposure to SARS-CoV-2;
167 thus, many subjects attended the hospital despite having minor symptoms to receive advice
168 and obtain a diagnosis. Importantly, in Chile, summer vacations go from December to the
169 first week of March, so despite frontiers closing on March 16 (only 13 days after the first
170 case), many cases were brought into the country by returning travelers. Indeed, 47 (12.3%)
171 of patients in our cohort had recently visited what was considered at the time a high-risk
172 country. These data suggests that strict isolation and contact tracing of imported cases may
173 have resulted in decreased spread to the general population.

174 A large proportion of patients in our cohort had a mild presentation, with only 18 (4.7%)
175 out of 381 requiring ICU care, consistent with prior studies.¹¹ Interestingly, only 3 patients
176 died during the hospitalization, representing a 3.4% of all patients requiring admission and

177 0.7% of the overall cohort. An in-hospital mortality rate of 3.4% is strikingly lower compared
178 to previous large reports from Wuhan (28%), the New York Area (21%) and other European
179 countries.¹²⁻¹⁵ This difference could be explained by a lower threshold for admission in our
180 cohort at a time when the healthcare system was not yet overloaded and bed capacity was
181 high. However, an in-hospital mortality of 22% reported from Germany at a time when the
182 healthcare capacity was not burdened argues against this as the sole explanation.¹⁴ Also,
183 patients in our cohort were younger (median age 49) compared to the New York, Wuhan
184 and German cohorts (median ages 63, 56 and 72 respectively). Age has been consistently
185 associated with disease severity and outcomes ^{12,16}, hence, it is likely a contributing factor
186 in the lower mortality rates observed in our cohort. Finally, previous cohorts ^{14,15} excluded
187 a large proportion of patients who were still hospitalized at the time of study closure,
188 biasing results towards an increased mortality rate due to the higher inclusion of patients
189 who died early in the course of hospitalization

190 The cohort presented here is mostly Hispanic, an ethnic population generally
191 underrepresented in medical research.¹⁷ Data from the United Kingdom and USA has shown
192 an increased risk of severe COVID-19 among ethnic minorities.¹⁸⁻²⁰ The low fatality and ICU
193 rate of our cohort suggests that the ethnicity issue might rather be a disparity problem.
194 Studies appropriately representing minority populations are sorely needed. Indeed, failing
195 to include an ethnically representative population leads to results that may not apply to
196 these groups, increasing the health inequality.

197 As reported elsewhere,²¹ higher CRP levels were associated with increased odds of need for
198 ICU care or in-hospital death. Further, our data suggest that elevated CRP levels in the first

199 24 hours of admission were a biomarker for severe clinical presentation of Covid-19. CRP is
200 an acute phase protein released mainly in response to interleukin-6 (IL-6), a cytokine that
201 has also been associated with disease severity in Covid-19.¹² Higher CRP levels are likely
202 associated with a higher inflammatory response, which may correspond with increased
203 tissue damage. CRP levels are widely available and generally cheaper than measuring IL-6
204 levels and therefore may represent an interesting biomarker to investigate in future studies.
205 Increased BMI was also associated with severe disease. Several theories have been raised
206 to explain this association, which was described before in other cohorts²², including
207 overactivated inflammation and immune response, decreased chest expansion, and
208 increased expression of ACE 2, among others.²²⁻²³ Although the mechanisms are beyond the
209 scope of this study, BMI seems to be a useful predictor of Covid-19 severity and therefore
210 obese patients should be considered a high-risk population. Finally, although the
211 SaTO₂/FiO₂ index on admission was not independently associated with our main outcome
212 (p=0.051), it was very close to our pre-established level of significance. These data, along
213 with a high biological plausibility suggests this index is worth exploring as a marker for the
214 development of severe Covid-19 disease in future studies.

215 The role of other biomarkers previously identified as predictors of in-hospital mortality or
216 ICU need were not confirmed in our cohort. These findings could be explained due to the
217 limited number of patients included in our series along with the low frequency of
218 occurrence of our primary outcomes (i.e. ICU admission and/or in-hospital mortality). In
219 addition, other relevant limitations of our study include that it is a single center effort and
220 its observational nature. Due to the latter, we did not explore treatment effects given our

221 limited ability to appropriately correct for potential confounders. However, our data were
222 prospectively collected with high quality standards and provide one of the few studies
223 contributing information from developing areas of the world, in this case South America. As
224 mentioned above, the data of this cohort mainly represent the initially affected high-income
225 population of Chile and a time of the pandemic where the healthcare system was not yet
226 overwhelmed. Therefore, future studies analyzing the general population attending to a
227 wider range of hospital centers and reflecting a systemic stress created by the large number
228 of patients infected with SARS-CoV-2 will be important to help understand the possible
229 influence of social and health disparities, and of the system overload in the outcomes of
230 Covid-19 patients.

231 In conclusion, among patients in our study, SARS-CoV-2 generally caused mild illness with a
232 case fatality rate of 0.7%. On admission, variables associated with the need of ICU care
233 and/or in-hospital mortality included BMI, CRP and SaTO₂/FiO₂, all of which are widely
234 available in low and middle resource settings such as Latin America.

235

236 **Declaration of Competing Interest**

237 All authors declare that they have no conflict or competing interests.

238 **Author contribution**

239 MRV: data analysis and interpretation, writing the original draft; AP: acquisition of data
240 and data analysis; IP: study design and critical review of the manuscript; MS: study design

241 and data acquisition; MB: study design and data acquisition; LP: data acquisition and
242 critical review of the manuscript; TW: study design and critical review of the manuscript;
243 MA: study design, data acquisition; PV: study design and critical review of the manuscript.
244 RA: study design, writing the original draft and critical review of the manuscript; JMM:
245 conception and design of the study design, critical review of the manuscript and final
246 approval of the version to be submitted.

247 † Clínica Alemana – Universidad del Desarrollo Covid-19 working group: Alejandra
248 Marcotti, Jorge Pérez, Luis Miguel Noriega, Pablo Gaete, Sebastián Solar, Silvina López,
249 Paulette Legarraga, , Valeska Vollrath, Alicia Anderson, Mirentxu Iruretagoyena, Jerónimo
250 Graf, Rodrigo Pérez, Manuela A. Roa

251 **Acknowledgments**

252 We would like to thank Betel Rivero, Patricia Vargas, Marco Maldonado and Magdalena
253 Canals for their valuable help with data collection and the Departamento Científico
254 Docente from Clinica Alemana de Santiago for their constant support.

255 **Funding Support**

256 This work was supported by FONDECYT 1171805 and by the ANID Millennium Science
257 Initiative/ Millennium Initiative for Collaborative Research on Bacterial Resistance,
258 MICROB-R, NCN17_081 (JMM) and by Departamento Científico Docente, Clinica Alemana
259 de Santiago (MRV and JMM).

260

261 **References**

262 1-Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
263 coronavirus in Wuhan, China [published correction appears in *Lancet*. 2020 Jan 30;]. *Lancet*.
264 2020; 395(10223):497-506.

265 2-Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new
266 coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-273.

267 3- Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in
268 China, 2019. *N Engl J Med*. 2020; 382(8):727-733.

269 4- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The
270 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and
271 naming it SARS-CoV-2. *Nat Microbiol*. 2020; 5(4):536-544.

272 5- Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N*
273 *Engl J Med*. 2020; 382(18):1708-1720.

274 6- Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019
275 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann*
276 *Intern Med*. 2020; 172(9):577-582.

277 7-Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19
278 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur Respir J*.
279 2020;55(5):2000524. Published 2020 May 7.

280 8-Wang K, Zuo P, Liu Y, et al. Clinical and laboratory predictors of in-hospital mortality in
281 patients with COVID-19: a cohort study in Wuhan, China [published online ahead of print,
282 2020 May 3]. *Clin Infect Dis*. 2020; ciaa538.

283 9-Porte L, Legarraga P, Vollrath V, et al. Evaluation of novel antigen-based rapid detection
284 test for the diagnosis of SARS-CoV-2 in respiratory samples [published online ahead of print,
285 2020 Jun 1]. *Int J Infect Dis*. 2020;S1201-9712(20)30405-7

286 10-Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
287 comorbidity in longitudinal studies: development and validation. *J Chronic Dis*.
288 1987;40(5):373-383.

289 11-Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019
290 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published online ahead of print,
291 2020 Feb 7]. *JAMA*. 2020;323(11):1061-1069

292 12-Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
293 with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears
294 in *Lancet*. 2020 Mar 28;395(10229):1038] [published correction appears in *Lancet*. 2020
295 Mar 28;395(10229):1038]. *Lancet*. 2020;395(10229):1054-1062.

296 13-Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities,
297 and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
298 [published online ahead of print, 2020 Apr 22] [published correction appears in doi:
299 10.1001/jama.2020.7681]. *JAMA*. 2020;323(20):2052-2059.

- 300 14-Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use, and
301 outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an
302 observational study [published online ahead of print, 2020 Jul 28]. *Lancet Respir Med*.
303 2020;S2213-2600(20)30316-7.
- 304 15-Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital
305 with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective
306 observational cohort study. *BMJ*. 2020;369:m1985
- 307 16-Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19
308 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur Respir*
309 *J*. 2020; **55**(5):2000524.
- 310 17- Smart A, Harrison E. The under-representation of minority ethnic groups in UK medical
311 research. *Ethn Health*. 2017;22(1):65-82Smart A, Harrison E.
- 312 18-Khunti K, Singh AK, Pareek M, Hanif W. Is ethnicity linked to incidence or outcomes of
313 covid-19?. *BMJ*. 2020;369:m1548. Published 2020 Apr 20
- 314 19-Public Health England. Disparities in the risk and outcomes of COVID-19. 2020.
315 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachmen](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/890258/disparities_review.pdf)
316 [t_data/file/890258/disparities review.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/890258/disparities_review.pdf)
- 317 20-Haynes N, Cooper LA, Albert MA; Association of Black Cardiologists. At the Heart of the
318 Matter: Unmasking and Addressing the Toll of COVID-19 on Diverse
319 Populations. *Circulation*. 2020;142(2):105-107.

320 21- Luo X, Zhou W, Yan X, et al. Prognostic value of C-reactive protein in patients with
321 COVID-19 [published online ahead of print, 2020 May 23]. *Clin Infect Dis*. 2020.

322 22- Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: a systematic review and meta-analysis
323 [published online ahead of print, 2020 Jun 30]. *J Med Virol*. 2020;10.

324 23- Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute
325 Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical
326 Ventilation. *Obesity (Silver Spring)*. 2020;28(7):1195-1199.

327

328




Figure 1: Clinical and laboratory markers within 24 hours of admission comparing ICU vs non-ICU patients.

of the SARS-CoV-2 pandemic.

	All outpatients N=293	All inpatients N=88	p-value
Characteristic			
Age, years	37 (28-45)	49 (39.5-65)	.00
Female gender	153 (52.2)	45 (51.1)	.85
Comorbidities			
Diabetes	5 (1.7)	6 (6.8)	.73
Hypertension	15 (5.1)	25 (28.4)	.00
BMI \geq 30	3 (1)	14 (15.9)	.002
Current smoker	7 (2.4)	6 (6.8)	.055
Obstructive pulmonary disease	10 (3.4)	6 (6.8)	.17
Malignancy	3 (1)	3 (3.4)	.14
Mean CCS (SD)	0.28 (0.7)	1.38 (2.0)	.00
Symptoms at the time of initial presentation			
Cough	170 (58)	64 (72.7)	.013
Fever	167 (43.8)	69 (78.4)	.00
Odynophagia	126 (43)	35 (39.8)	.59
Fatigue	91 (31.1)	38 (43.2)	.036
Anosmia or Ageusia	28 (9.6)	7 (8)	.65
Chest pain	9 (2.4)	5 (5.7)	.26
Dyspnea	3 (1.0)	4 (4.5)	.048

Data are median (IQR), n (%), or n/N (%). p values were calculated by Mann-Whitney U test, χ^2 test, or Fisher's exact test, as appropriate. χ^2 test comparing all subcategories.

	All hospitalized N=88	ICU care or death N=18	Non-ICU care N=70	p-value
Demographics				
Age, years	49 (39.5-65)	68.5 (59-72)	46 (38-58)	.000
Female gender	45 (51.1)	3 (16.7)	42 (60)	.003
Symptoms on admission				
Cough	64 (72.7)	13 (72.2)	51 (72.9)	.96
Fever	69 (78.4)	15 (83.3)	54 (77.1)	.64
Anosmia	7 (8)	0	7 (10)	.16
Ageusia	3 (3.4)	0	3 (4.3)	.37
Odynophagia	35 (39.8)	7 (38.9)	28 (40)	.93
Fatigue	38 (43.2)	6 (33.3)	32 (45.7)	.35
Dyspnea	4 (4.5)	2 (11.1)	2 (2.9)	.16
Chest pain	5 (5.7)	0	5 (7.1)	.24
Comorbidities				
Diabetes	6 (6.8)	3 (16.7)	3 (4.3)	.06
Hypertension	25 (28.4)	10 (55.6)	15 (21.4)	.004
Mean BMI (SD)	26.5 (3.8)	29.2 (3.9)	25.7 (3.5)	.002
Smoker	6 (6.8)	1 (5.6)	5 (7.1)	.81
COPD or Asthma	6 (6.8)	3 (16.7)	3 (4.3)	0.097
Mean CCS (SD)	1.38(1.96)	3(2.3)	0.96 (1.62)	.001
Physical exam				
Heart rate	81 (74-89)	86 (75-97)	80.5(74-88)	.23
T >37.5 C (axillary)	42/48 (87.5)	8/9 (88.9)	34/39 (87.2)	0.89
Respiratory rate	20 (18-22)	21(20-24)	20(18-22)	.13
SBP <90 Or MAP < 65 mmHg	9/81 (11.1)	1/13 (7.7)	8/68 (11.8)	1.0
SaTO2%/FiO2	452.4 (404.2-461.9)	317.9 (248.6-447.6)	457.14 (447.6-466.7)	.000
Chronic Medications				
ARBs/ACEi	18/87 (20.7)	9/17 (52.9)	9/70 (12.9)	.00
Steroids	4 (4.5)	4 (22.2)	0	.001

Table 3: Laboratory findings within 24h of admission comparing patients who required ICU care or died to those who did not require ICU

	All patients	ICU care or death	No ICU care	p-value
Hemoglobin, g/dL	14.1 (13.1-14.8)	10.2(10.1-12.5)	14.3 (13.5-15)	.13
White blood cell count, mm ³ < 4500	23/73 (31.5)	1/15 (6.7)	22/58 (37.9)	.096
> 11500	2/73 (2.7)	1/15 (6.7)	1/58 (1.7)	.024
Lymphocyte count, mm ³ < 1000	31/73 (42.5)	12/15 (80)	19/58 (32.8)	.001
Neutrophil count, mm ³ <2500	3605 (2453-4714) 19/72 (26.4)	4723 (4095-6707) 0	3266 (2304-4192) 19/57 (33.3)	.006 .013
Neutrophil/Lymphocyte ratio	2.8 (1.9-5.5)	7.0 (5.3-9.4)	2.3 (1.8-3.7)	.00
Platelet count, mm ³ < 100	182(136-236) 2/73 (2.7)	175(131-252) 0	186 (136-236) 2/58 (3.4)	.58 .067
C-reactive protein mg/dL >0.5	5/73 (75.3)	15/15 (100)	40/58 (69)	.015
Procalcitonin ng/mL	0.05 (0.04-0.1)	0.17 (0.08-0.3)	0.05 (0.03-0.07)	.003
Ferritina ng/mL > 300	20/25 (80)	11/11 (100)	9/14 (64.3)	.046
D-dimer, ng/mL > 500	32/68 (47.1)	10/14 (71.4)	22/54 (40.7)	.040
Prothrombin time, s	88.5 (81-99.5)	85 (73-87)	92 (85-100)	.014
Aspartate aminotransferase, U/L	27.3 (21.1-35)	26.5 (23.2-42)	27.3 (20.9-35)	.90
Alanine aminotransferase, U/L	26.1(16.4-38.6)	28.3 (15.2-38.6)	25.7 (16.4-40)	.54
Total bilirubin, mg/dL	0.36 (0.25-0.48)	0.51 (0.38-0.7)	0.33 (0.24-0.42)	.001
Albumin, g/dL	4.05 (3.8-4.4)	3.7 (3.4-4.1)	4.1 (3.9-4.4)	.003
Lactate dehydrogenase U/L	222 (177-296)	264 (203-411)	205 (171-275)	.011
Troponin T, ng/mL > 14	3.2 (3-7.3) 7/46 (15.2)	13.3 (4-30.2) 5/11 (45.5)	3 (3-5.3) 2/35 (5.7)	.043 .005
Sodium mmol/L < 135	18/77 (23.4)	11/18 (61.1)	7/59 (11.9)	.00
Creatinine, mg/dL	0.80 (0.72-0.97)	0.87 (0.73-0.99)	0.78 (0.72-0.93)	.93

Data are median (IQR) or n/N where N is the total number of patients with available data.

Table 4

Multivariate Logistic Regression Analysis Risk Factors for ICU or death for patients admitted with COVID-19

	OR (95% CI)	p-value
BMI	1.436 (1.042-1.979)	0.027
C-reactive protein	1.505 (1.107-2.047)	0.009